Next Article in Journal
Comparison of Four SARS-CoV-2 Neutralization Assays
Next Article in Special Issue
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Previous Article in Journal
Platforms Exploited for SARS-CoV-2 Vaccine Development
Previous Article in Special Issue
An Absence of Epstein–Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination
Review

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

1
Department of Neurology, Faculty of Medicine, Université Saint Joseph, Beirut B.P. 11-5076, Lebanon
2
Department of Neurology, Hotel-Dieu de France Hospital, Beirut 16-6830, Lebanon
3
Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
*
Author to whom correspondence should be addressed.
Received: 5 July 2020 / Revised: 6 August 2020 / Accepted: 11 August 2020 / Published: 26 December 2020
(This article belongs to the Special Issue Multiple Sclerosis and Its Complications: Clinical Trials)
In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly. Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions are increasingly used early in the disease course. These newer DMTs include oral therapies (teriflunomide, dimethyl fumarate, fingolimod, siponimod, ozanimod, and cladribine) and infusion therapies (natalizumab, alemtuzumab, and ocrelizumab), and are associated with better control of disease activity and long-term outcomes in patients with MS compared to older injectable therapies (interferon beta and glatiramer acetate). However, they are associated with safety concerns and subsequent monitoring requirements. Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach. View Full-Text
Keywords: multiple sclerosis; disease modifying therapies; safety; long-term outcomes multiple sclerosis; disease modifying therapies; safety; long-term outcomes
MDPI and ACS Style

Jalkh, G.; Abi Nahed, R.; Macaron, G.; Rensel, M. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines 2021, 9, 12. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9010012

AMA Style

Jalkh G, Abi Nahed R, Macaron G, Rensel M. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines. 2021; 9(1):12. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9010012

Chicago/Turabian Style

Jalkh, Georges, Rachelle Abi Nahed, Gabrielle Macaron, and Mary Rensel. 2021. "Safety of Newer Disease Modifying Therapies in Multiple Sclerosis" Vaccines 9, no. 1: 12. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9010012

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop